The global Regenerative Medicine market size was valued at US$ 41490 million in 2024 and is forecast to a readjusted size of USD 136440 million by 2031 with a CAGR of 18.7% during review period.
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body鈥檚 innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.
Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and 鈥渢he vanguard of 21st century healthcare鈥� by the U.S. Department of Health and Human Services.
Global Regenerative Medicine key players include J & J (DePuy Synthes), Medtronic, Allergan(Acelity), Zimmer Biomet, etc. Global top four manufacturers hold a share about 10%.
North America is the largest market, with a share about 25%, followed by Europe, and Asia Pacific, both have a share over 40 percent.
In terms of product, Tissue Engineering is the largest segment, with a share over 40%. And in terms of application, the largest application is Dermatology, followed by Cardiovascular, CNS, Orthopedic, etc.
This report is a detailed and comprehensive analysis for global Regenerative Medicine market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Regenerative Medicine market size and forecasts, in consumption value ($ Million), 2020-2031
Global Regenerative Medicine market size and forecasts by region and country, in consumption value ($ Million), 2020-2031
Global Regenerative Medicine market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031
Global Regenerative Medicine market shares of main players, in revenue ($ Million), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Regenerative Medicine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Regenerative Medicine market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include J & J (DePuy Synthes), Medtronic, Zimmer Biomet, Stryker, Allergan(Acelity), MiMedx Group, Organogenesis, Fujifilm Cellular Dynamics, Osiris Therapeutics, Vcanbio, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Regenerative Medicine market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Cell Therapy
Tissue Engineering
Biomaterial
Other
麻豆原创 segment by Application
Dermatology
Cardiovascular
CNS
Orthopedic
Others
麻豆原创 segment by players, this report covers
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Regenerative Medicine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Regenerative Medicine, with revenue, gross margin, and global market share of Regenerative Medicine from 2020 to 2025.
Chapter 3, the Regenerative Medicine competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Regenerative Medicine market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Regenerative Medicine.
Chapter 13, to describe Regenerative Medicine research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Regenerative Medicine by Type
1.3.1 Overview: Global Regenerative Medicine 麻豆原创 Size by Type: 2020 Versus 2024 Versus 2031
1.3.2 Global Regenerative Medicine Consumption Value 麻豆原创 Share by Type in 2024
1.3.3 Cell Therapy
1.3.4 Tissue Engineering
1.3.5 Biomaterial
1.3.6 Other
1.4 Global Regenerative Medicine 麻豆原创 by Application
1.4.1 Overview: Global Regenerative Medicine 麻豆原创 Size by Application: 2020 Versus 2024 Versus 2031
1.4.2 Dermatology
1.4.3 Cardiovascular
1.4.4 CNS
1.4.5 Orthopedic
1.4.6 Others
1.5 Global Regenerative Medicine 麻豆原创 Size & Forecast
1.6 Global Regenerative Medicine 麻豆原创 Size and Forecast by Region
1.6.1 Global Regenerative Medicine 麻豆原创 Size by Region: 2020 VS 2024 VS 2031
1.6.2 Global Regenerative Medicine 麻豆原创 Size by Region, (2020-2031)
1.6.3 North America Regenerative Medicine 麻豆原创 Size and Prospect (2020-2031)
1.6.4 Europe Regenerative Medicine 麻豆原创 Size and Prospect (2020-2031)
1.6.5 Asia-Pacific Regenerative Medicine 麻豆原创 Size and Prospect (2020-2031)
1.6.6 South America Regenerative Medicine 麻豆原创 Size and Prospect (2020-2031)
1.6.7 Middle East & Africa Regenerative Medicine 麻豆原创 Size and Prospect (2020-2031)
2 Company Profiles
2.1 J & J (DePuy Synthes)
2.1.1 J & J (DePuy Synthes) Details
2.1.2 J & J (DePuy Synthes) Major Business
2.1.3 J & J (DePuy Synthes) Regenerative Medicine Product and Solutions
2.1.4 J & J (DePuy Synthes) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 J & J (DePuy Synthes) Recent Developments and Future Plans
2.2 Medtronic
2.2.1 Medtronic Details
2.2.2 Medtronic Major Business
2.2.3 Medtronic Regenerative Medicine Product and Solutions
2.2.4 Medtronic Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 Medtronic Recent Developments and Future Plans
2.3 Zimmer Biomet
2.3.1 Zimmer Biomet Details
2.3.2 Zimmer Biomet Major Business
2.3.3 Zimmer Biomet Regenerative Medicine Product and Solutions
2.3.4 Zimmer Biomet Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Zimmer Biomet Recent Developments and Future Plans
2.4 Stryker
2.4.1 Stryker Details
2.4.2 Stryker Major Business
2.4.3 Stryker Regenerative Medicine Product and Solutions
2.4.4 Stryker Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Stryker Recent Developments and Future Plans
2.5 Allergan(Acelity)
2.5.1 Allergan(Acelity) Details
2.5.2 Allergan(Acelity) Major Business
2.5.3 Allergan(Acelity) Regenerative Medicine Product and Solutions
2.5.4 Allergan(Acelity) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Allergan(Acelity) Recent Developments and Future Plans
2.6 MiMedx Group
2.6.1 MiMedx Group Details
2.6.2 MiMedx Group Major Business
2.6.3 MiMedx Group Regenerative Medicine Product and Solutions
2.6.4 MiMedx Group Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 MiMedx Group Recent Developments and Future Plans
2.7 Organogenesis
2.7.1 Organogenesis Details
2.7.2 Organogenesis Major Business
2.7.3 Organogenesis Regenerative Medicine Product and Solutions
2.7.4 Organogenesis Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 Organogenesis Recent Developments and Future Plans
2.8 Fujifilm Cellular Dynamics
2.8.1 Fujifilm Cellular Dynamics Details
2.8.2 Fujifilm Cellular Dynamics Major Business
2.8.3 Fujifilm Cellular Dynamics Regenerative Medicine Product and Solutions
2.8.4 Fujifilm Cellular Dynamics Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 Fujifilm Cellular Dynamics Recent Developments and Future Plans
2.9 Osiris Therapeutics
2.9.1 Osiris Therapeutics Details
2.9.2 Osiris Therapeutics Major Business
2.9.3 Osiris Therapeutics Regenerative Medicine Product and Solutions
2.9.4 Osiris Therapeutics Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Osiris Therapeutics Recent Developments and Future Plans
2.10 Vcanbio
2.10.1 Vcanbio Details
2.10.2 Vcanbio Major Business
2.10.3 Vcanbio Regenerative Medicine Product and Solutions
2.10.4 Vcanbio Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.10.5 Vcanbio Recent Developments and Future Plans
2.11 CCBC
2.11.1 CCBC Details
2.11.2 CCBC Major Business
2.11.3 CCBC Regenerative Medicine Product and Solutions
2.11.4 CCBC Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.11.5 CCBC Recent Developments and Future Plans
2.12 Cytori
2.12.1 Cytori Details
2.12.2 Cytori Major Business
2.12.3 Cytori Regenerative Medicine Product and Solutions
2.12.4 Cytori Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.12.5 Cytori Recent Developments and Future Plans
2.13 Celgene
2.13.1 Celgene Details
2.13.2 Celgene Major Business
2.13.3 Celgene Regenerative Medicine Product and Solutions
2.13.4 Celgene Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.13.5 Celgene Recent Developments and Future Plans
2.14 Vericel Corporation
2.14.1 Vericel Corporation Details
2.14.2 Vericel Corporation Major Business
2.14.3 Vericel Corporation Regenerative Medicine Product and Solutions
2.14.4 Vericel Corporation Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.14.5 Vericel Corporation Recent Developments and Future Plans
2.15 Guanhao Biotech
2.15.1 Guanhao Biotech Details
2.15.2 Guanhao Biotech Major Business
2.15.3 Guanhao Biotech Regenerative Medicine Product and Solutions
2.15.4 Guanhao Biotech Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.15.5 Guanhao Biotech Recent Developments and Future Plans
2.16 Mesoblast
2.16.1 Mesoblast Details
2.16.2 Mesoblast Major Business
2.16.3 Mesoblast Regenerative Medicine Product and Solutions
2.16.4 Mesoblast Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.16.5 Mesoblast Recent Developments and Future Plans
2.17 AMAG Pharmaceuticals (CBR)
2.17.1 AMAG Pharmaceuticals (CBR) Details
2.17.2 AMAG Pharmaceuticals (CBR) Major Business
2.17.3 AMAG Pharmaceuticals (CBR) Regenerative Medicine Product and Solutions
2.17.4 AMAG Pharmaceuticals (CBR) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.17.5 AMAG Pharmaceuticals (CBR) Recent Developments and Future Plans
2.18 ViaCord
2.18.1 ViaCord Details
2.18.2 ViaCord Major Business
2.18.3 ViaCord Regenerative Medicine Product and Solutions
2.18.4 ViaCord Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.18.5 ViaCord Recent Developments and Future Plans
2.19 CordLife
2.19.1 CordLife Details
2.19.2 CordLife Major Business
2.19.3 CordLife Regenerative Medicine Product and Solutions
2.19.4 CordLife Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.19.5 CordLife Recent Developments and Future Plans
2.20 Integra LifeSciences
2.20.1 Integra LifeSciences Details
2.20.2 Integra LifeSciences Major Business
2.20.3 Integra LifeSciences Regenerative Medicine Product and Solutions
2.20.4 Integra LifeSciences Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.20.5 Integra LifeSciences Recent Developments and Future Plans
2.21 Nuvasive
2.21.1 Nuvasive Details
2.21.2 Nuvasive Major Business
2.21.3 Nuvasive Regenerative Medicine Product and Solutions
2.21.4 Nuvasive Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.21.5 Nuvasive Recent Developments and Future Plans
2.22 Cook Biotech
2.22.1 Cook Biotech Details
2.22.2 Cook Biotech Major Business
2.22.3 Cook Biotech Regenerative Medicine Product and Solutions
2.22.4 Cook Biotech Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.22.5 Cook Biotech Recent Developments and Future Plans
2.23 Japan Tissue Engineering
2.23.1 Japan Tissue Engineering Details
2.23.2 Japan Tissue Engineering Major Business
2.23.3 Japan Tissue Engineering Regenerative Medicine Product and Solutions
2.23.4 Japan Tissue Engineering Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.23.5 Japan Tissue Engineering Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Regenerative Medicine Revenue and Share by Players (2020-2025)
3.2 麻豆原创 Share Analysis (2024)
3.2.1 麻豆原创 Share of Regenerative Medicine by Company Revenue
3.2.2 Top 3 Regenerative Medicine Players 麻豆原创 Share in 2024
3.2.3 Top 6 Regenerative Medicine Players 麻豆原创 Share in 2024
3.3 Regenerative Medicine 麻豆原创: Overall Company Footprint Analysis
3.3.1 Regenerative Medicine 麻豆原创: Region Footprint
3.3.2 Regenerative Medicine 麻豆原创: Company Product Type Footprint
3.3.3 Regenerative Medicine 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Regenerative Medicine Consumption Value and 麻豆原创 Share by Type (2020-2025)
4.2 Global Regenerative Medicine 麻豆原创 Forecast by Type (2026-2031)
5 麻豆原创 Size Segment by Application
5.1 Global Regenerative Medicine Consumption Value 麻豆原创 Share by Application (2020-2025)
5.2 Global Regenerative Medicine 麻豆原创 Forecast by Application (2026-2031)
6 North America
6.1 North America Regenerative Medicine Consumption Value by Type (2020-2031)
6.2 North America Regenerative Medicine 麻豆原创 Size by Application (2020-2031)
6.3 North America Regenerative Medicine 麻豆原创 Size by Country
6.3.1 North America Regenerative Medicine Consumption Value by Country (2020-2031)
6.3.2 United States Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
6.3.3 Canada Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
6.3.4 Mexico Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
7 Europe
7.1 Europe Regenerative Medicine Consumption Value by Type (2020-2031)
7.2 Europe Regenerative Medicine Consumption Value by Application (2020-2031)
7.3 Europe Regenerative Medicine 麻豆原创 Size by Country
7.3.1 Europe Regenerative Medicine Consumption Value by Country (2020-2031)
7.3.2 Germany Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
7.3.3 France Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
7.3.4 United Kingdom Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Russia Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
7.3.6 Italy Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8 Asia-Pacific
8.1 Asia-Pacific Regenerative Medicine Consumption Value by Type (2020-2031)
8.2 Asia-Pacific Regenerative Medicine Consumption Value by Application (2020-2031)
8.3 Asia-Pacific Regenerative Medicine 麻豆原创 Size by Region
8.3.1 Asia-Pacific Regenerative Medicine Consumption Value by Region (2020-2031)
8.3.2 China Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8.3.3 Japan Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8.3.4 South Korea Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8.3.5 India Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Southeast Asia Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Australia Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
9 South America
9.1 South America Regenerative Medicine Consumption Value by Type (2020-2031)
9.2 South America Regenerative Medicine Consumption Value by Application (2020-2031)
9.3 South America Regenerative Medicine 麻豆原创 Size by Country
9.3.1 South America Regenerative Medicine Consumption Value by Country (2020-2031)
9.3.2 Brazil Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
9.3.3 Argentina Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
10 Middle East & Africa
10.1 Middle East & Africa Regenerative Medicine Consumption Value by Type (2020-2031)
10.2 Middle East & Africa Regenerative Medicine Consumption Value by Application (2020-2031)
10.3 Middle East & Africa Regenerative Medicine 麻豆原创 Size by Country
10.3.1 Middle East & Africa Regenerative Medicine Consumption Value by Country (2020-2031)
10.3.2 Turkey Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
10.3.3 Saudi Arabia Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
10.3.4 UAE Regenerative Medicine 麻豆原创 Size and Forecast (2020-2031)
11 麻豆原创 Dynamics
11.1 Regenerative Medicine 麻豆原创 Drivers
11.2 Regenerative Medicine 麻豆原创 Restraints
11.3 Regenerative Medicine Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Regenerative Medicine Industry Chain
12.2 Regenerative Medicine Upstream Analysis
12.3 Regenerative Medicine Midstream Analysis
12.4 Regenerative Medicine Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering
听
听
*If Applicable.
